Panic Disorder

1. Overview
2. DSM-5 Diagnostic Criteria
3. Distinguishing Panic Disorder from GAD and Agoraphobia
4. Neurobiology: CO2 Hypersensitivity and Interoceptive Conditioning
5. Causes and Risk Factors
6. Nocturnal Panic Attacks
7. Assessment Tools
8. Treatment: CBT and Interoceptive Exposure
9. Pharmacotherapy: CANMAT 2023 Guidelines
10. Avoiding Benzodiazepine Dependence
11. Recovery, Self-Management, and Prognosis
12. Key Research Papers

Overview

Panic Disorder is characterized by recurrent, unexpected panic attacks combined with at least one month of persistent concern about future attacks or their consequences, or significant behavioral changes aimed at avoiding attacks. It affects approximately 2–3% of the population over a lifetime, with onset typically occurring in late adolescence to the mid-30s. Women are diagnosed at 2–3 times the rate of men.

A panic attack is an abrupt surge of intense fear or discomfort that peaks within minutes and includes at least 4 of 13 recognized somatic or cognitive symptoms:

• Palpitations, pounding heart, or accelerated heart rate
• Sweating
• Trembling or shaking
• Shortness of breath or feeling smothered
• Feelings of choking
• Chest pain or discomfort
• Nausea or abdominal distress
• Dizziness, unsteadiness, light-headedness, or faintness
• Derealization (feelings of unreality) or depersonalization (feeling detached from oneself)
• Fear of losing control or "going crazy"
• Fear of dying
• Paresthesias (numbness or tingling sensations)
• Chills or hot flashes

Panic attacks themselves can occur in the context of many anxiety disorders and other conditions. What defines Panic Disorder is that the attacks are unexpected (not cued by a specific trigger) and that the person develops persistent worry or behavioral change in response to them.

Back to Table of Contents

DSM-5 Diagnostic Criteria

The DSM-5 diagnosis of Panic Disorder requires all four criteria:

• Criterion A: Recurrent unexpected panic attacks — abrupt surges of intense fear or discomfort reaching a peak within minutes, with 4 or more of the 13 symptoms listed above.
• Criterion B: At least one attack has been followed by one month (or more) of either: (1) persistent concern or worry about additional panic attacks or their consequences (e.g., losing control, having a heart attack, "going crazy"), or (2) a significant maladaptive change in behavior related to the attacks (e.g., behaviors designed to avoid having panic attacks such as avoidance of exercise or unfamiliar situations).
• Criterion C: The disturbance is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition (e.g., hyperthyroidism, cardiopulmonary disorders).
• Criterion D: The disturbance is not better explained by another mental disorder, such as the panic attacks not occurring only in response to feared social situations (as in Social Anxiety Disorder), in response to circumscribed phobic objects or situations (as in Specific Phobia), in response to obsessions (as in OCD), in response to reminders of traumatic events (as in PTSD), or in response to separation from attachment figures (as in Separation Anxiety Disorder).

A key distinction within the DSM-5 framework is between expected (cued) panic attacks, which occur in anticipation of or exposure to a specific feared object or situation, and unexpected (uncued) panic attacks, which arise without any obvious trigger. Panic Disorder requires at least some attacks to be unexpected. The DSM-5 also separately codes Agoraphobia, which frequently co-occurs with Panic Disorder but is now its own independent diagnosis.

Back to Table of Contents

Distinguishing Panic Disorder from GAD and Agoraphobia

Several anxiety conditions overlap clinically with Panic Disorder. Accurate diagnosis determines which treatment approach is most effective.

Generalized Anxiety Disorder (GAD)

GAD presents with chronic, diffuse worry across multiple life domains (health, finances, relationships, work), not episodic terror. While panic attacks can occur in GAD, they are typically cued by the content of the patient's worry rather than arising unexpectedly. The dominant experience in GAD is persistent low-grade anxiety, not discrete high-intensity attacks. GAD patients typically worry about real-life problems; panic disorder patients fear the panic itself and its physical sensations.

Agoraphobia

Agoraphobia is a separate DSM-5 diagnosis characterized by marked fear or anxiety about at least 2 of 5 situation types: using public transportation, being in open spaces, being in enclosed places, standing in line or being in a crowd, or being outside the home alone. The fear centers on the possibility that escape would be difficult or help unavailable if a panic attack or incapacitating symptoms occur. Approximately 40% of people with Panic Disorder develop Agoraphobia, but the two conditions are now coded separately because Agoraphobia can exist without a history of panic attacks.

Social Anxiety Disorder

In Social Anxiety Disorder, panic attacks are situationally cued and occur specifically in social or performance situations. The fear is of scrutiny or embarrassment, not of the panic attack itself.

Medical Differentials

Medical conditions that can mimic or trigger panic attacks must be excluded before diagnosis, including:

• Hyperthyroidism — check TSH, free T4
• Pheochromocytoma — check plasma or urine catecholamines if hypertension is present
• Cardiac arrhythmia — ECG, Holter monitor
• Hypoglycemia — fasting glucose, HbA1c
• Vestibular disorders — dizziness as a primary complaint
• Seizure disorders — particularly temporal lobe epilepsy
• Pulmonary embolism — in acute presentations with chest pain and dyspnea

A basic workup (CBC, metabolic panel, TSH, ECG) is appropriate before initiating psychiatric treatment.

Back to Table of Contents

Neurobiology: CO2 Hypersensitivity and Interoceptive Conditioning

Panic Disorder has a well-characterized neurobiological profile that directly informs its treatments.

CO2 Hypersensitivity and the Suffocation False Alarm Theory

Panic disorder patients show heightened sensitivity to CO2 inhalation. Breathing 5–35% CO2 reliably provokes full panic attacks in approximately 70% of people with Panic Disorder, compared with 10–15% of healthy controls. Donald Klein proposed the suffocation false alarm theory: panic represents a misfiring of an evolved suffocation monitor that is excessively sensitive to rising CO2 and lactic acid levels. According to this model, the brain's alarm system interprets elevated CO2 as a signal of impending suffocation and triggers an emergency response — the panic attack — even when no actual threat is present.

This explains several clinical observations: why lactate infusion provokes panic in susceptible individuals, why hyperventilation (which lowers CO2) can paradoxically both cause panic symptoms and temporarily abort attacks, and why breathing retraining (slowing the breathing rate to allow CO2 to normalize) is an effective intervention.

Interoceptive Conditioning: The Fear-of-Fear Cycle

David Barlow's interoceptive conditioning model proposes that internal bodily sensations — tachycardia, dizziness, shortness of breath — become conditioned stimuli that trigger panic through a fear-of-fear cycle. The sequence is:

1. A panic attack occurs, producing intense bodily sensations
2. The person learns to associate these sensations with danger
3. Normal variations in heart rate, breathing, or dizziness are now interpreted catastrophically
4. This catastrophic interpretation produces anxiety, which amplifies the sensations
5. A positive feedback loop escalates to full panic

This model directly motivates interoceptive exposure — deliberately inducing the feared sensations in a safe context to break the conditioned association and allow habituation.

Neural Circuitry

Neuroimaging and pharmacological challenge studies implicate several systems:

• Locus coeruleus — hyperactivation of this norepinephrine hub produces the autonomic surge characteristic of panic
• Amygdala/hippocampus fear network — heightened reactivity to threat signals, including interoceptive cues
• Prefrontal cortex — reduced top-down inhibitory control over amygdala responses
• Serotonergic and GABAergic systems — hypofunctioning contributes to reduced inhibition of fear circuits; targets of effective pharmacotherapy (SSRIs, benzodiazepines)
• Periaqueductal gray (PAG) — encodes defensive behaviors including freezing and flight; dysregulation may underlie the overwhelming quality of panic

Back to Table of Contents

Causes and Risk Factors

Panic Disorder arises from an interaction between biological vulnerability and environmental triggers.

Genetic Factors

Heritability is estimated at approximately 40%, indicating a substantial but not deterministic genetic contribution. No single gene has been identified; risk is polygenic. First-degree relatives of people with Panic Disorder have a 3–4 times higher lifetime risk.

Temperamental Risk Factors

• Neuroticism — a broad trait of emotional reactivity and negative affect; the single strongest predictor of anxiety disorder onset
• Anxiety sensitivity — a specific tendency to fear anxiety-related sensations themselves (e.g., believing that a racing heart is dangerous); the Anxiety Sensitivity Index (ASI) is the best single predictor of panic vulnerability
• Behavioral inhibition in childhood — a temperamental pattern of withdrawal from novelty associated with later anxiety disorders

Developmental and Environmental Factors

• Childhood separation anxiety disorder is a significant risk factor
• A stressful life event frequently precedes the first panic attack — commonly interpersonal loss, serious illness in oneself or a family member, or major life transitions
• A history of physical or sexual abuse increases risk
• Respiratory disease (asthma, COPD) is associated with elevated panic disorder rates, likely through increased CO2 sensitivity and respiratory-focused interoceptive learning

Biological and Substance Factors

• Female sex — 2–3 times the prevalence compared to males; hormonal fluctuations (premenstrual, postpartum, perimenopause) are associated with increased panic vulnerability
• Smoking — strongly associated with onset and maintenance of panic disorder; nicotine's effects on respiratory sensitivity are one proposed mechanism
• Caffeine — adenosine antagonism and increased sympathetic arousal can trigger attacks in susceptible individuals; moderate reduction is a reasonable first step
• Cannabis — particularly high-THC products can precipitate panic attacks and worsen the disorder
• Stimulant use — amphetamines, cocaine, and energy drinks can trigger attacks

Back to Table of Contents

Nocturnal Panic Attacks

Between 10–30% of people with Panic Disorder experience nocturnal panic attacks — episodes in which they awaken from sleep in the midst of a full panic attack. These are clinically significant because they are distressing, frequently lead to avoidance of sleep, and are associated with more severe overall illness.

Key Features

• Occur during non-REM sleep (stages 2–3), not during dreaming (REM sleep) — this distinguishes them from PTSD nightmares, which occur during REM
• The person wakes already in panic, without a preceding dream narrative
• Attacks meet full criteria (4+ symptoms, fear of dying or losing control, etc.)
• They occur without any obvious external trigger

Differential Diagnosis

Nocturnal panic must be distinguished from:

• Sleep apnea — arousals from apnea can produce fear and dyspnea but are accompanied by oximetry desaturation; polysomnography differentiates
• PTSD nightmares — REM-stage, content-rich, traumatic imagery; the person wakes with fear but also with nightmare recall
• Night terrors (sleep terrors) — occur in non-REM slow-wave sleep, typically in children; the person screams but is not fully awake and has no recall in the morning
• Hypoglycemia — nocturnal hypoglycemia in diabetic patients can produce sympathetic symptoms mimicking panic; blood glucose check differentiates

Clinical Implications

Nocturnal panic is associated with higher rates of agoraphobic avoidance, greater overall symptom severity, and more frequent comorbid depression. CBT protocols specifically address nocturnal attacks through interoceptive exposure to the hypnagogic state and cognitive restructuring of catastrophic beliefs about dying in sleep.

Back to Table of Contents

Assessment Tools

Standardized measures facilitate accurate diagnosis, severity rating, and treatment monitoring.

Panic Disorder Severity Scale (PDSS)

A 7-item clinician-rated scale covering panic attack frequency, distress during attacks, anticipatory anxiety, agoraphobic fear and avoidance, interoceptive avoidance, and work/social impairment. Total scores range 0–28; a score of 7 or above indicates moderate-to-severe illness, and a reduction to below 7 is commonly used as a treatment response threshold. The PDSS is the primary outcome measure in most clinical trials.

Patient Health Questionnaire Panic Disorder Module (PHQ-PD)

A brief self-report screener derived from the PHQ. Two initial screening questions about unexpected panic attacks and a cluster of attacks; positive screen prompts a full diagnostic interview. Useful in primary care settings where panic disorder is frequently missed or misattributed to cardiac disease.

Mobility Inventory for Agoraphobia (MI)

Assesses avoidance across 26 agoraphobic situations, rated separately when accompanied by a companion and when alone. Provides a quantitative measure of functional restriction and is sensitive to treatment-related improvement in avoidance behavior.

Anxiety Sensitivity Index (ASI)

A 16-item self-report measure of the tendency to fear anxiety-related sensations. Scores predict panic vulnerability better than trait anxiety measures. Three subscales assess physical, cognitive, and social concerns about anxiety symptoms. The ASI is the single best screening tool for identifying individuals at elevated risk for developing Panic Disorder and is a core outcome measure in interoceptive exposure interventions.

Back to Table of Contents

Treatment: CBT and Interoceptive Exposure

Cognitive-Behavioral Therapy (CBT) is the gold-standard psychological treatment for Panic Disorder, with effect sizes of d = 0.9–1.5 compared to waitlist controls and number-needed-to-treat (NNT) estimates of approximately 3–4. A standard course is 12–15 sessions and includes multiple components.

Psychoeducation

Patients learn the physiology of the panic cycle: how the fight-or-flight response works, why it produces the 13 panic symptoms, and how catastrophic misinterpretation amplifies benign sensations into perceived emergencies. Understanding that panic is not dangerous — that no one has ever died from a panic attack — begins to erode the fear-of-fear cycle. This is often reported as one of the most immediately helpful components.

Cognitive Restructuring

CBT targets the catastrophic misinterpretation of bodily sensations that drives the cycle. Common catastrophic cognitions include: "This pounding in my chest means I'm having a heart attack," "I'm going to faint," "I'm losing my mind." Therapist and patient work together to examine the evidence for and against these interpretations, identify cognitive distortions (probability overestimation, catastrophizing), and develop realistic alternative appraisals.

Interoceptive Exposure

The most distinctive and potent component of panic-specific CBT. Patients deliberately induce the physical sensations they fear through structured exercises in session, then practice at home. Standard exercises include:

• Spinning in a chair (30–60 seconds) — provokes dizziness and derealization
• Hyperventilation (1–2 minutes) — provokes tingling, lightheadedness, shortness of breath
• Breathing through a narrow coffee straw — provokes air hunger and sense of suffocation
• Running in place or climbing stairs — provokes tachycardia and flushing
• Tensing muscles while holding breath — provokes chest tightness and pressure

Repeated exposure to these sensations in a safe context produces habituation — the sensations become less threatening because the predicted catastrophe never occurs. This is inhibitory learning: a new safety memory is formed that competes with the original fear memory.

In Vivo Situational Exposure

For patients with agoraphobic avoidance, graduated exposure to avoided situations is conducted through a fear hierarchy. Common avoided situations include driving, crowds, elevators, exercise, being far from home, and supermarkets. Exposure is prolonged and repeated until anxiety subsides.

Breathing Retraining

Diaphragmatic breathing at a paced rate of 4–6 breath cycles per minute (slower than the normal 12–16/min) raises CO2 and counteracts hyperventilation-driven symptoms. It is taught as a coping skill for managing early panic symptoms, though some protocols de-emphasize it to prevent reliance on safety behaviors. The current emphasis is on using breathing retraining as a skill for daily regulation rather than an escape behavior during attacks.

Back to Table of Contents

Pharmacotherapy: CANMAT 2023 Guidelines

Medication is an effective alternative to CBT and can be combined with it for enhanced outcomes. CANMAT 2023 guidelines align closely with NICE and APA recommendations.

First-Line: SSRIs and SNRIs

Selective serotonin reuptake inhibitors (SSRIs) are the medications of choice. Agents with established efficacy in RCTs include:

• Sertraline 50–200 mg/day
• Escitalopram 10–20 mg/day
• Paroxetine 20–60 mg/day (controlled-release formulation preferred for tolerability)
• Fluoxetine 20–60 mg/day
• Venlafaxine XR (SNRI) 75–225 mg/day — equally effective, useful when depression is comorbid

Critical prescribing note: Patients with Panic Disorder are highly sensitive to activating side effects in the first 1–2 weeks of SSRI treatment (increased anxiety, restlessness, insomnia, "jitteriness syndrome"). This paradoxical early worsening can cause patients to discontinue prematurely. Start at half the usual starting dose (e.g., sertraline 12.5–25 mg rather than 50 mg) and titrate slowly over 2–4 weeks. Warn patients explicitly that this initial phase occurs and that it resolves.

Meta-analyses show SSRIs and CBT produce equivalent outcomes in randomized trials; combination therapy is modestly superior to either alone.

Second-Line

• Tricyclic antidepressants (TCAs) — imipramine and clomipramine have strong evidence but are limited by anticholinergic effects, weight gain, orthostatic hypotension, and lethality in overdose
• Mirtazapine 15–45 mg/day — useful when sedation or appetite improvement are desired; some evidence in panic disorder

Third-Line

• MAOIs (phenelzine, tranylcypromine) — highly effective but require dietary tyramine restriction and have dangerous drug interactions; reserved for treatment-resistant cases

Treatment Duration

Pharmacotherapy should be continued for a minimum of 12 months after achieving remission to prevent relapse. Discontinuation should be gradual — reducing dose by 25% every 4–8 weeks — to minimize discontinuation syndrome and monitor for relapse signals. Many patients benefit from longer-term treatment.

Back to Table of Contents

Avoiding Benzodiazepine Dependence

Benzodiazepines (alprazolam, clonazepam, lorazepam, diazepam) provide rapid and reliable relief from panic attacks and are still frequently prescribed. However, they should not be used as first-line treatment for Panic Disorder, and their long-term use is contraindicated by current guidelines including CANMAT 2023.

Why Benzodiazepines Are Problematic

• Tolerance develops within weeks: the anxiolytic effect diminishes while physical dependence builds
• Physical dependence and withdrawal: abrupt discontinuation produces rebound anxiety more severe than baseline, insomnia, tremor, and in high doses, seizures
• Cognitive impairment: particularly in older adults; increased fall risk, memory interference, and slowed processing
• Interference with CBT: benzodiazepines taken during exposure exercises prevent the fear habituation and inhibitory learning that drives therapeutic change; patients attribute coping to the drug rather than their own capacity
• Rebound panic: interdose anxiety and rebound panic with short-acting agents (alprazolam) can actually increase the frequency of panic episodes

When They May Be Used

If benzodiazepines are used, CANMAT recommends limiting them to:

• Short-term bridge therapy (2–4 weeks) while SSRIs are being titrated to therapeutic doses
• Acute management of severe situational anxiety in limited, defined circumstances

Discontinuation Protocol

Patients already on long-term benzodiazepines require a gradual taper — typically 5–10% dose reduction every 1–2 weeks, often over months. Switching to a longer-acting agent (diazepam) before tapering reduces inter-dose withdrawal symptoms. Psychological support — ideally CBT specifically targeting benzodiazepine discontinuation — is critical during taper and significantly improves success rates.

Back to Table of Contents

Recovery, Self-Management, and Prognosis

Panic Disorder is a highly treatable condition. With evidence-based treatment, 50–70% of patients achieve remission (defined as no panic attacks and minimal anticipatory anxiety). However, recurrence is common: 20–30% of patients experience relapse if treatment is stopped prematurely, particularly if CBT was not part of the treatment package.

Predictors of Good Outcome

• Early treatment (shorter duration of untreated illness)
• Completion of a full CBT course with interoceptive exposure
• Absence of severe agoraphobia
• Absence of comorbid personality disorder
• Low anxiety sensitivity at baseline

Self-Management Strategies

Several evidence-based self-management approaches complement formal treatment:

• Aerobic exercise — regular cardiovascular exercise (at least 3 sessions per week, 20+ minutes each) independently reduces panic severity. Exercise also serves as a form of interoceptive exposure, allowing habituation to elevated heart rate and breathing. One meta-analysis found exercise produced moderate effect sizes comparable to relaxation training
• Caffeine reduction — eliminating or significantly reducing coffee, energy drinks, and tea can reduce baseline physiological arousal and lower attack frequency in susceptible individuals
• Sleep hygiene — irregular sleep and sleep deprivation lower the threshold for panic attacks; consistent sleep scheduling and good sleep hygiene are foundational
• Mindfulness-Based Stress Reduction (MBSR) — mindfulness training develops the capacity to observe anxious sensations without catastrophic appraisal; multiple RCTs support its efficacy as an adjunct
• CBT self-help workbooks — validated workbooks (e.g., Barlow and Craske's Mastery of Your Anxiety and Panic) have demonstrated efficacy equivalent to therapist-delivered treatment in mild-to-moderate cases; used with or without minimal therapist contact
• Alcohol avoidance — while alcohol provides short-term anxiolysis, withdrawal produces rebound anxiety and increases panic vulnerability; alcohol use disorder is a frequent complication of untreated panic disorder

Long-Term Outlook

With combined pharmacotherapy and CBT, most patients achieve substantial functional recovery. The skills learned in CBT — recognizing the panic cycle, tolerating physical sensations without catastrophizing, approaching feared situations — are permanent tools that protect against relapse even after treatment ends. Patients who complete interoceptive exposure report being less afraid of their own bodies and less likely to catastrophize normal physical fluctuations, which constitutes a durable change in how panic disorder affects daily life.

Back to Table of Contents

Key Research Papers

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602. PMID 15939837
2. Klein DF. False suffocation alarms, spontaneous panics, and related conditions: an integrative hypothesis. Arch Gen Psychiatry. 1993;50(4):306–317. PMID 8466392
3. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA. 2000;283(19):2529–2536. PMID 10815116
4. Clark DM. A cognitive approach to panic. Behav Res Ther. 1986;24(4):461–470. PMID 3741311
5. Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on the etiology of panic disorder. Psychol Rev. 2001;108(1):4–32. PMID 11212633
6. Roy-Byrne PP, Craske MG, Stein MB. Panic disorder. Lancet. 2006;368(9540):1023–1032. PMID 16980119
7. Shear MK, Brown TA, Barlow DH, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571–1575. PMID 9356566
8. Latas M, Starcevic V, Trajkovic G, Bogojevic G. Predictors of comorbid axis I and axis II diagnoses in patients with panic disorder. Psychiatry Res. 2012;200(2–3):588–593. PMID 22626735
9. Bandelow B, Lichte T, Rudolf S, Wiltink J, Beutel ME. The efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183–192. PMID 25932596
10. Craske MG, Treanor M, Conway CC, Zbozinek T, Vervliet B. Maximizing exposure therapy: an inhibitory learning approach. Behav Res Ther. 2014;58:10–23. PMID 24864005
11. Craske MG, Barlow DH. Panic disorder and agoraphobia. In: Barlow DH, ed. Clinical Handbook of Psychological Disorders. 5th ed. Guilford Press; 2014. [Book chapter — standard reference for CBT protocol]
12. Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther. 1986;24(1):1–8. PMID 3947307

PubMed Topic Searches

• Panic Disorder — CBT and Cognitive Behavioral Therapy
• Panic Disorder — Interoceptive Exposure
• Panic Disorder — SSRI Treatment
• Panic Disorder — CO2 Hypersensitivity
• Nocturnal Panic Attacks
• Panic Disorder — Benzodiazepine Dependence

Back to Table of Contents

Connections

• Anxiety
• PTSD
• Depression
• OCD
• Insomnia
• ADHD
• Bipolar Disorder
• Addiction
• Breathwork
• Stress Management
• Magnesium
• Ashwagandha
• L-Theanine

Featured Videos